Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises

Axsome Therapeutics, Inc. (AXSM) announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.Per the company, Symbravo, a novel, oral medicine, offers a multi-mechanistic approach to treating migraine. It targets multiple pathways underlying a migraine attack.AXSM expects to launch Symbravo in the United States in about four months.Shares of AXSM were up 3.5% on Jan. 30 following the news announcement.The stock has rallied 20.8% ...